Live Earnings Conference Call: Cidara Therapeutics will host a live Q2 2025 earnings call on August 7, 2025 at 5:00PM ET. Follow this link to get details and listen to Cidara Therapeutics' Q2 2025 earnings call when it goes live. Get details. NASDAQ:CDTX Cidara Therapeutics (CDTX) Stock Price, News & Analysis $61.99 +0.22 (+0.36%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$52.20 -9.79 (-15.79%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Cidara Therapeutics Stock (NASDAQ:CDTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cidara Therapeutics alerts:Sign Up Key Stats Today's Range$60.59▼$62.7350-Day Range$21.02▼$64.8552-Week Range$10.14▼$66.94Volume561,040 shsAverage Volume593,208 shsMarket Capitalization$1.25 billionP/E RatioN/ADividend YieldN/APrice Target$57.29Consensus RatingBuy Company Overview Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California. Read More Cidara Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreCDTX MarketRank™: Cidara Therapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 832nd out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.6 / 5Analyst RatingBuy Consensus RatingCidara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCidara Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cidara Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Cidara Therapeutics are expected to decrease in the coming year, from ($8.74) to ($14.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cidara Therapeutics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cidara Therapeutics is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCidara Therapeutics has a P/B Ratio of 4.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cidara Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.98% of the float of Cidara Therapeutics has been sold short.Short Interest Ratio / Days to CoverCidara Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cidara Therapeutics has recently increased by 40.99%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCidara Therapeutics does not currently pay a dividend.Dividend GrowthCidara Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.85 Percentage of Shares Shorted12.98% of the float of Cidara Therapeutics has been sold short.Short Interest Ratio / Days to CoverCidara Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cidara Therapeutics has recently increased by 40.99%, indicating that investor sentiment is decreasing significantly. News and Social Media2.7 / 5News Sentiment0.86 News SentimentCidara Therapeutics has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cidara Therapeutics this week, compared to 3 articles on an average week.Search Interest12 people have searched for CDTX on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cidara Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Cidara Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $99,999,988.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.89% of the stock of Cidara Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 35.82% of the stock of Cidara Therapeutics is held by institutions.Read more about Cidara Therapeutics' insider trading history. Receive CDTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cidara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CDTX Stock News HeadlinesCidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025July 24, 2025 | globenewswire.comSegal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara TherapeuticsJuly 7, 2025 | businesswire.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant. | The Oxford Club (Ad)Warner Bros., Cidara, LENZ Therapeutics, and More Stocks See Action From Activist InvestorsJuly 3, 2025 | msn.comCidara Therapeutics Added to Russell 2000 and Russell 3000 Indexes Recognizing Corporate Progress - NasdaqJuly 2, 2025 | nasdaq.comCidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)July 1, 2025 | globenewswire.comCidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® IndexesJune 30, 2025 | globenewswire.comCidara Therapeutics Inc (CDTX) - Investing.com UKJune 29, 2025 | uk.investing.comSee More Headlines CDTX Stock Analysis - Frequently Asked Questions How have CDTX shares performed this year? Cidara Therapeutics' stock was trading at $26.88 on January 1st, 2025. Since then, CDTX stock has increased by 130.6% and is now trading at $61.99. How were Cidara Therapeutics' earnings last quarter? Cidara Therapeutics, Inc. (NASDAQ:CDTX) announced its earnings results on Thursday, May, 8th. The biotechnology company reported ($1.66) earnings per share for the quarter, beating analysts' consensus estimates of ($5.45) by $3.79. Read the conference call transcript. When did Cidara Therapeutics' stock split? Cidara Therapeutics's stock reverse split before market open on Wednesday, April 24th 2024.The 1-20 reverse split was announced on Wednesday, April 24th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Cidara Therapeutics IPO? Cidara Therapeutics (CDTX) raised $60 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers. Who are Cidara Therapeutics' major shareholders? Top institutional investors of Cidara Therapeutics include Aberdeen Group plc (1.29%), Simplex Trading LLC, Jennison Associates LLC (0.24%) and West Michigan Advisors LLC (0.08%). Insiders that own company stock include Ra Capital Management, LP, Jeffrey Stein, Taylor Sandison, Leslie Tari, Shane Ward, Preetam Shah and Paul Daruwala. View institutional ownership trends. How do I buy shares of Cidara Therapeutics? Shares of CDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cidara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cidara Therapeutics investors own include Meta Platforms (META), VBI Vaccines (VBIV), SCYNEXIS (SCYX), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Sorrento Therapeutics (SRNE) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings5/08/2025Today8/07/2025Next Earnings (Estimated)8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CDTX CIK1610618 Webwww.cidara.com Phone(858) 752-6170FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Price Target for Cidara Therapeutics$57.29 High Price Target$75.00 Low Price Target$45.00 Potential Upside/Downside-7.6%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($29.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$169.83 million Net MarginsN/A Pretax Margin-61,454.97% Return on Equity-73.04% Return on Assets-54.28% Debt Debt-to-Equity RatioN/A Current Ratio3.87 Quick Ratio3.87 Sales & Book Value Annual Sales$302 thousand Price / Sales4,138.96 Cash FlowN/A Price / Cash FlowN/A Book Value$14.92 per share Price / Book4.15Miscellaneous Outstanding Shares20,164,000Free Float19,380,000Market Cap$1.25 billion OptionableNo Data Beta1.18 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:CDTX) was last updated on 8/7/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.